Gohealth Inc

Gohealth Inc(GOCO)股票分析

$0.305

+0.016 (+5.14%)收盤時

Loading chart…
High
0.325
Open
0.290
VWAP
0.31
Vol
2.74M
Mkt Cap
94.10M
Low
0.290
Amount
839.53K
EV/EBITDA, TTM
-0.57

GoHealth, Inc. is a medicare-focused digital health company that operates in a health insurance marketplace. The Company primarily offers Medicare plans, including Medicare Advantage, Medicare Supplement and prescription drug plans. Its technology platform leverages modern machine-learning algorithms, powered by insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer’s specific needs. Its Medicare Advantage offerings include Special Needs Plans (SNPs). SNPs are special kinds of Medicare Advantage plans that have benefits covering special health care or financial needs. Its Marketplace technology features decision support tools and integrates with health plan partner enterprise systems, enabling agents to quickly select the right health insurance plan for each consumer based on their specific needs and enroll them in those plans. It offers Encompass Connect and Encompass Engage services to its health plan partners.

AI analysis of Gohealth Inc (GOCO)

sell

GoHealth is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading at deeply distressed levels, the company has entered Chapter 11 restructuring, and the latest news confirms severe financial stress. Even though the price is oversold technically, the fundamental situation dominates and makes this a poor long-term purchase. Given the user's impatience and unwillingness to wait for a better entry, the clear answer is to avoid buying GOCO now.

估值指標

The current forward P/E ratio for Gohealth Inc (GOCO) is 588.24, compared to its 5-year average forward P/E of 58.75.

Forward P/E

Strongly Overvalued
5Y Average P/E
58.75
Current P/E
588.24
高估
254.64
低估
-137.15

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
8.40
Current EV/EBITDA
-0.57
高估
16.37
低估
0.43

Forward P/S

Undervalued
5Y Average P/S
0.16
Current P/S
0.02
高估
0.27
低估
0.06

Alphio AI Price Scenarios for GOCO

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%GOCO

$7.39

情境價格

B

Base

Base · 50%GOCO

$7.22

情境價格

B

Bear

Bear · 25%GOCO

$7.19

情境價格

Whales holding GOCO

G

Glendon Capital Management L.P.

+ HoldingGOCO

-1.98%

3M Return

事件時間軸

2025-12-16 (ET)

17:10:00

GoHealth Files to Sell 9.57M Shares of Class A Common Stock

2025-11-13 (ET)

07:08:17

GoHealth CEO emphasizes prioritizing 'quality over quantity'

07:07:33

GoHealth Announces Q3 Earnings Per Share of $11.80 Compared to 46 Cents Last Year

2025-08-07 (ET)

07:34:38

GoHealth reports Q2 EPS ($5.10) vs ($2.70) last year

2025-05-13 (ET)

07:12:57

GoHealth reports Q1 EPS (52c) vs ($1.04) last year

資訊

GOCO FAQ — answered by Alphio AI

GoHealth, Inc. is a medicare-focused digital health company that operates in a health insurance marketplace. The Company primarily offers Medicare plans, including Medicare Advantage, Medicare Supplement and prescription drug plans. Its technology platform leverages modern machine-learning algorithms, powered by insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer’s specific needs. Its Medicare Advantage offerings include Special Needs Plans (SNPs). SNPs are special kinds of Medicare Advantage plans that have benefits covering special health care or financial needs. Its Marketplace technology features decision support tools and integrates with health plan partner enterprise systems, enabling agents to quickly select the right health insurance plan for each consumer based on their specific needs and enroll them in those plans. It offers Encompass Connect and Encompass Engage services to its health plan partners. It operates in the Financials sector (INSURANCE AGENTS, BROKERS & SERVICE industry).

GoHealth is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading at deeply distressed levels, the company has entered Chapter 11 restructuring, and the latest news confirms severe financial stress. Even though the price is oversold technically, the fundamental situation dominates and makes this a poor long-term purchase. Given the user's impatience and unwillingness to wait for a better entry, the clear answer is to avoid buying GOCO now.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始